Evidence map›Paper›PMID 34428312›Full record

ArticleJournal of medical virology2022

Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS-CoV-2 infection.

Amanda I Portilho, Valéria O Silva, Cintia M Ahagon, Elaine M Matsuda, Elaine L de Oliveira, Edilene P R da Silveira, Ana K de Souza Lima, José A L Lindoso, Ivana B de Campos, Marisa A Hong and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Amanda I PortilhoInstitute Adolfo Lutz, Center of Immunology, São Paulo, Sao Paulo, Brazil.ORCID 0000-0003-0875-5910
Valéria O SilvaInstitute Adolfo Lutz, Center of Virology, São Paulo, Sao Paulo, Brazil.ORCID 0000-0002-5346-9633
Cintia M AhagonInstitute Adolfo Lutz, Center of Virology, São Paulo, Sao Paulo, Brazil.ORCID 0000-0001-8233-0369
Elaine M MatsudaDepartment of Santo André Health, Infectious Diseases Outpatient Clinic, Santo André, Sao Paulo, Brazil.ORCID 0000-0002-0254-4154
Elaine L de OliveiraInstitute Adolfo Lutz, Center of Immunology, São Paulo, Sao Paulo, Brazil.
Edilene P R da SilveiraInstitute Adolfo Lutz, Center of Immunology, São Paulo, Sao Paulo, Brazil.
Ana K de Souza LimaInstitute of Infectology Emilio Ribas, São Paulo, Sao Paulo, Brazil.
José A L LindosoInstitute of Infectology Emilio Ribas, São Paulo, Sao Paulo, Brazil.ORCID 0000-0002-4405-4401
Ivana B de CamposInstitute Adolfo Lutz, Santo André Regional Center, Santo André, São Paulo, Brazil.ORCID 0000-0003-0334-0572
Marisa A HongInstitute Adolfo Lutz, Center of Immunology, São Paulo, Sao Paulo, Brazil.ORCID 0000-0003-1219-8299
Elizabeth De GaspariInstitute Adolfo Lutz, Center of Immunology, São Paulo, Sao Paulo, Brazil.ORCID 0000-0001-8332-2248
Luís F de Macedo BrígidoInstitute Adolfo Lutz, Center of Virology, São Paulo, Sao Paulo, Brazil.ORCID 0000-0002-1022-7837
Instituto Adolfo Lutz · BRInstituto de Infectologia Emílio Ribas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many aspects of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), such as its role in protection after natural infection, are still unclear. We evaluated IgA and IgG response to spike subunits 1 and 2 (S1 and S2) and Nucleocapsid proteins of SARS-COV-2 in serum samples of 109 volunteers with viral RNA detected or seroconversion with different clinical evolution (asymptomatic, mild, moderate, and severe coronavirus disease 2019), using the ViraChip® Test Kit. We observed that the quantification of antibodies to all antigens had a positive correlation to disease severity, which was strongly associated with the presence of comorbidities. Seroreversion was not uncommon even during the short (median of 77 days) observation, occurring in 15% of mild-asymptomatic cases at a median of 55 days for IgG and 46 days for IgA. The time to reach the maximal antibody response did not differ significantly among recovered and deceased volunteers. Our study illustrated the dynamic of anti-S1, anti-N, and anti-S2 IgA and IgG antibodies, and suggests that high production of IgG and IgA does not guarantee protection to disease severity and that functional responses that have been studied by other groups, such as antibody avidity, need further attention.

Indexed as

AdultAgedAged, 80 and overAntibodies, ViralCoronavirus Nucleocapsid ProteinsCOVID-19FemaleHumansImmunoglobulin AImmunoglobulin GMaleMiddle AgedPhosphoproteinsSARS-CoV-2SeroconversionSpike Glycoprotein, CoronavirusAntibodies, ViralCoronavirus Nucleocapsid ProteinsImmunoglobulin AImmunoglobulin Gnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19nucleocapsidSARS-CoV-2spikeViraChip®

Identifiers

PMID34428312
PMCPMC8661980
OpenAlexW3194775772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.